Edwards Lifesciences Completes $4.2B Sale Of Critical Care To BD, Announces $1B Share Repurchase, And Board Authorizes Additional $1.5B For Future Buybacks
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences has completed the $4.2 billion sale of its Critical Care division to Becton, Dickinson and Company (BD). Additionally, Edwards announced a $1 billion share repurchase program and its board has authorized an additional $1.5 billion for future buybacks.
September 03, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Becton, Dickinson and Company (BD) has acquired Edwards Lifesciences' Critical Care division for $4.2 billion.
The acquisition of the Critical Care division is a strategic move for BD, potentially enhancing its product offerings and market position, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Edwards Lifesciences has sold its Critical Care division to BD for $4.2 billion, announced a $1 billion share repurchase, and authorized an additional $1.5 billion for future buybacks.
The sale of the Critical Care division provides significant capital, which is being used for share repurchases, indicating confidence in the company's future. The authorization of additional buybacks suggests a strong financial position and potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100